PriceTargets.com logo

NYSE:SQZ - SQZ Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.33
  • Forecasted Upside: 221.32 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$11.93 As of 10/20/2021 01:00 AM ET
▲ +0.07 (0.59%)

This chart shows the closing price for SQZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SQZ Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SQZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SQZ

Analyst Price Target is $38.33
▲ +221.32% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for SQZ Biotechnologies in the last 3 months. The average price target is $38.33, with a high forecast of $40.00 and a low forecast of $37.00. The average price target represents a 221.32% upside from the last price of $11.93.

This chart shows the closing price for SQZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in SQZ Biotechnologies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2021Brookline Capital ManagementReiterated RatingBuyN/A
1/7/2021Evercore ISIInitiated CoverageOutperformHigh
11/24/2020Stifel NicolausInitiated CoverageBuy$38.00Low
11/24/2020Bank of AmericaInitiated CoverageBuy$37.00Low
11/24/2020BTIG ResearchInitiated CoverageBuy$40.00Low
(Data available from 10/21/2016 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2021

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
SQZ Biotechnologies logo
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $11.93
Low: $11.61
High: $11.96

50 Day Range

MA: $13.36
Low: $11.46
High: $15.77

52 Week Range

Now: $11.93
Low: $11.15
High: $36.49

Volume

52,018 shs

Average Volume

155,734 shs

Market Capitalization

$334.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of SQZ Biotechnologies?

The following Wall Street sell-side analysts have issued reports on SQZ Biotechnologies in the last twelve months: Bank of America Co., Brookline Capital Management, BTIG Research, Evercore ISI, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for SQZ.

What is the current price target for SQZ Biotechnologies?

3 Wall Street analysts have set twelve-month price targets for SQZ Biotechnologies in the last year. Their average twelve-month price target is $38.33, suggesting a possible upside of 221.3%. BTIG Research has the highest price target set, predicting SQZ will reach $40.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $37.00 for SQZ Biotechnologies in the next year.
View the latest price targets for SQZ.

What is the current consensus analyst rating for SQZ Biotechnologies?

SQZ Biotechnologies currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SQZ will outperform the market and that investors should add to their positions of SQZ Biotechnologies.
View the latest ratings for SQZ.

What other companies compete with SQZ Biotechnologies?

Other companies that are similar to SQZ Biotechnologies include Atara Biotherapeutics, Coherus BioSciences, Sangamo Therapeutics, Caribou Biosciences, Agenus, Vaxcyte, Monte Rosa Therapeutics, Century Therapeutics, Krystal Biotech, Omega Therapeutics, Icosavax, Immunovant, iTeos Therapeutics, BioAtla and Cullinan Oncology.

How do I contact SQZ Biotechnologies' investor relations team?

SQZ Biotechnologies' physical mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The official website for SQZ Biotechnologies is www.sqzbiotech.com.